Top Story Today
A Chinese Anesthetic Just Crossed the Pacific and Made FDA History
The FDA approved cipepofol, the first China-originated innovative IV anesthetic ever cleared for the U.S. market, and it's not a copycat. Haisco Pharmaceutical's drug knocks patients out at one-fifth the dose of propofol (the gold standard for decades) and slashes injection-site pain from 77% to 18%. The FDA even waived Phase 2 trials entirely, a rare vote of confidence for any drug, let alone one from a Chinese company in the highest-stakes clinical setting imaginable: rendering patients unconscious on an operating table.
Why it matters: This approval flips the traditional West-to-East flow of pharmaceutical innovation. The FDA essentially declared it trusts a China-developed molecule to safely put American patients under general anesthesia, a credibility milestone that signals the era of one-directional drug development is over.
Read more →Deals and M&A
Biogen Spent $5.6B on Apellis, Then Torched the Science
Weeks after closing its $5.6 billion Apellis acquisition, Biogen paused or killed the majority of the company's research programs, keeping only the two products already generating revenue. Gene-editing collaborations, brain-penetrating complement inhibitors, RNA therapies: all frozen or gone. It's a familiar playbook in big pharma M&A, where "strategic acquisition" really means "we wanted your sales force and your cash flow, not your ideas."
Read more →Lilly Paid $202M for a Company With Zero Drugs
Eli Lilly acquired preclinical biotech Engage Biologics for up to $202 million, buying a DNA delivery platform called Tethosome that hasn't been tested in a single human. The logic: genetic medicine has a shipping problem, and the company that solves delivery wins the whole category. It's the latest piece in Lilly's systematic assembly of a genetic medicine toolkit, funded by GLP-1 cash flow.
Read more →A $5 Million Biotech Just Bought a CAR-T Company for $320 Million
Liminatus Pharma, with $1.9 million in cash and a market cap of roughly $5 million, agreed to acquire CAR-T biotech InnocsAI in an all-stock deal valued at $320 million. The CEO of the buyer also has a controlling stake in an entity that partly owns the seller. History says deals born from desperation rarely end well for shareholders.
Read more →Clinical Setbacks
Immunovant Paid $39M to Walk Away From a Drug That Didn't Work
Two Phase 3 trials of batoclimab in thyroid eye disease came up empty, and Immunovant is eating $39 million in contractual costs related to the discontinuation just to clean up. The FcRn inhibitor class has now essentially struck out in TED, even though the same mechanism works brilliantly in neuromuscular diseases. Immunovant's entire future now rides on its next-gen candidate, IMVT-1402.
Read more →Five Patients Quit and Annexon Lost a Third of Its Value
Five dropouts in a 28-patient Huntington's disease trial wiped out roughly a third of Annexon's market cap in early 2022. Three patients experienced autoimmune side effects, but all had pre-existing risk markers, and all resolved after stopping treatment. Analysts mostly held their Buy ratings, calling the selloff fear-driven. In a disease with a 3.5% clinical success rate, though, investors don't give second chances easily.
Read more →Funding and Partnerships
Alumis Raised Half a Billion Dollars in Six Months Without Selling a Single Pill
Clinical-stage Alumis priced its 2024 IPO at $16 per share, raising roughly $250 million, just three months after closing a $259 million Series C. Shares opened 16% below the offer price, but the company later raised another $345 million in a follow-on at $17. Its TYK2 inhibitor for psoriasis hit all Phase 3 endpoints, and the capital haul reflects an IPO market that's wide open for late-stage immunology plays.
Read more →Incyte Bet $120M That AI Can Build Its Next Pipeline
Incyte committed $120 million upfront (including a $40 million equity stake) to expand its AI drug discovery collaboration with Genesis Molecular AI, covering at least five new programs. Total payments could top $1 billion. The kicker: Incyte will feed proprietary research data into Genesis' models, building what could become a self-improving discovery engine trained on its own experiments.
Read more →A Tiny UK Biotech Posted Positive Data in Insmed's Backyard
Infex Therapeutics reported positive Phase 2a results for RESP-X, an antibody targeting Pseudomonas aeruginosa in bronchiectasis patients. The safety was spotless, the drug supports quarterly dosing, and there was a hint of fewer lung flare-ups. As a small biotech up against Insmed's billion-dollar Brinsupri franchise, Infex isn't competing head-on; it's carving out a niche for the sickest subset of patients.
Read more →